 Lupus Erythematosus, Systemic
"Lupus Erythematosus, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Descriptor ID |
D008180
|
| MeSH Number(s) |
C17.300.480 C20.111.590
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lupus Erythematosus, Systemic".
Below are MeSH descriptors whose meaning is more specific than "Lupus Erythematosus, Systemic".
This graph shows the total number of publications written about "Lupus Erythematosus, Systemic" by people in this website by year, and whether "Lupus Erythematosus, Systemic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 1 | 0 | 1 | | 1981 | 1 | 2 | 3 | | 1982 | 3 | 0 | 3 | | 1983 | 3 | 0 | 3 | | 1984 | 2 | 2 | 4 | | 1985 | 0 | 1 | 1 | | 1986 | 2 | 0 | 2 | | 1987 | 1 | 0 | 1 | | 1988 | 1 | 1 | 2 | | 1989 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 | | 1992 | 1 | 1 | 2 | | 1994 | 1 | 1 | 2 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 2 | 3 | | 1998 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 2 | 0 | 2 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 1 | 2 | | 2004 | 4 | 3 | 7 | | 2005 | 7 | 0 | 7 | | 2006 | 3 | 0 | 3 | | 2007 | 6 | 1 | 7 | | 2008 | 7 | 2 | 9 | | 2009 | 9 | 0 | 9 | | 2010 | 12 | 0 | 12 | | 2011 | 9 | 0 | 9 | | 2012 | 13 | 0 | 13 | | 2013 | 8 | 0 | 8 | | 2014 | 3 | 1 | 4 | | 2015 | 6 | 2 | 8 | | 2016 | 2 | 0 | 2 | | 2017 | 4 | 1 | 5 | | 2018 | 4 | 2 | 6 | | 2020 | 1 | 2 | 3 | | 2021 | 4 | 1 | 5 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lupus Erythematosus, Systemic" by people in Profiles.
-
Moussa T, Abdelhak M, Edens C. Pseudotumor cerebri syndrome in children with systemic lupus erythematosus: case series and review. Pediatr Rheumatol Online J. 2022 Apr 15; 20(1):29.
-
Papa V, Brainer J, Henriksen KJ, Cenacchi G, Chang A. Extraglomerular immune complex deposition in lupus nephritis. Lupus. 2022 Jan; 31(1):19-27.
-
Lee CT, Strek ME. The other connective tissue disease-associated interstitial lung diseases: Sjogren's syndrome, mixed connective tissue disease, and systemic lupus erythematosus. Curr Opin Pulm Med. 2021 09 01; 27(5):388-395.
-
Kawai VK, Shi M, Liu G, Feng Q, Wei W, Chung CP, Walunas TL, Gordon AS, Linneman JG, Hebbring SJ, Harley JB, Cox NJ, Roden DM, Stein CM, Mosley JD. Pleiotropy of systemic lupus erythematosus risk alleles and cardiometabolic disorders: A phenome-wide association study and inverse-variance weighted meta-analysis. Lupus. 2021 Jul; 30(8):1264-1272.
-
Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, Kim M, Berdofe A, Radhakrishnan M, Jung E, Sandrock AW, Smirnakis K, Popescu C, de Moor C. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
Chang A, Clark MR, Ko K. Cellular aspects of the pathogenesis of lupus nephritis. Curr Opin Rheumatol. 2021 03 01; 33(2):197-204.
-
Chen PM, Wilson PC, Shyer JA, Veselits M, Steach HR, Cui C, Moeckel G, Clark MR, Craft J. Kidney tissue hypoxia dictates T cell-mediated injury in murine lupus nephritis. Sci Transl Med. 2020 04 08; 12(538).
-
Kinloch AJ, Cascino MD, Dai J, Bermea RS, Ko K, Vesselits M, Dragone LL, Mor Vaknin N, Legendre M, Markovitz DM, Okoreeh MK, Townsend MJ, Clark MR. Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis. Lupus. 2020 May; 29(6):569-577.
-
Cohen RD, Bhayat F, Blake A, Travis S. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. J Crohns Colitis. 2020 Feb 10; 14(2):192-204.
-
Hanscombe KB, Morris DL, Noble JA, Dilthey AT, Tombleson P, Kaufman KM, Comeau M, Langefeld CD, Alarcon-Riquelme ME, Gaffney PM, Jacob CO, Sivils KL, Tsao BP, Alarcon GS, Brown EE, Croker J, Edberg J, Gilkeson G, James JA, Kamen DL, Kelly JA, McCune J, Merrill JT, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Scofield H, Utset T, Wallace DJ, Weisman MH, Kimberly RP, Harley JB, Lewis CM, Criswell LA, Vyse TJ. Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum Mol Genet. 2018 11 01; 27(21):3813-3824.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|